PT-141 Research Peptide

PT-141 is often described simply as an MC4R agonist, but the pharmacology is broader. The US prescribing information for bremelanotide lists it as a non-selective agonist with a potency order of MC1R, then MC4R, MC3R, MC5R and, weakest by far, MC2R. All five are G-protein-coupled receptors that raise cyclic AMP when activated, so a cAMP readout in cells expressing a single cloned receptor is the standard way to compare them.

Which receptor matters depends on where the tissue is. MC4R is concentrated in hypothalamic regions including the medial preoptic area and the paraventricular nucleus, and it is the subtype regarded as most relevant to PT-141’s central actions. MC1R sits mainly on melanocytes, and its activation explains why focal skin darkening was recorded as an adverse event in clinical studies. MC3R, also expressed in the brain, has drawn far less attention in PT-141 work, so its contribution remains an open question.

PT-141 was developed by Palatin Technologies of Cranbury, New Jersey, and early papers from the company described activity at MC3R and MC4R in rats and non-human primates. The first clinical programme used a nasal formulation, partnered with King Pharmaceuticals. In August 2007 the US FDA raised concerns that the compound increased blood pressure in some trial participants, and in May 2008 Palatin halted that programme as King withdrew.

Development later restarted with an injectable formulation. Two Phase 3 studies, numbered 301 and 302, enrolled premenopausal women, and in January 2017 AMAG Pharmaceuticals licensed North American rights. After approval under the brand name Vyleesi, AMAG and Palatin ended their agreement in 2020, returning the product to Palatin, which sold it to Cosette Pharmaceuticals in December 2023. The licensed product is a regulated finished medicine; Crown Peptides PT-141 is freeze-dried research material with the same peptide sequence.

Blood pressure shaped the PT-141 story more than any other safety measure. The Vyleesi label reports maximum rises of about 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after treatment and usually back to baseline within 12 hours, with heart rate falling by up to 5 beats per minute. Uncontrolled hypertension and known cardiovascular disease are listed as contraindications.

A 2022 review of the whole development programme, covering roughly 3,500 participants in 43 completed studies, described the ambulatory monitoring results as small and transient but statistically significant (Learn more). Those findings fit a wider picture in which central MC4R signalling helps set sympathetic tone, which is why PT-141 data are often discussed alongside human MC4R genetics.

Early animal work tracked where PT-141 acts in the brain. When given systemically to rats, it increased c-Fos immunoreactivity, a marker of recently activated neurons, in the hypothalamus. Later studies at Concordia University in Montreal, run with Palatin scientists, used ovariectomised, hormone-primed female rats in a paced-mating arena where the female controls the timing of contact (Learn more).

In that model PT-141 increased one class of appetitive behaviour, solicitations, while lordosis and pacing were unchanged and there was no general increase in movement. The same pattern appeared when the peptide was infused into the lateral ventricles or directly into the medial preoptic area, but not the ventromedial hypothalamus. Combined with c-Fos mapping in hypothalamic and limbic regions, the authors proposed that presynaptic MC4Rs on dopamine terminals in the medial preoptic area are a key site of action, a hypothesis that keeps this region at the centre of melanocortin behavioural neuroscience.